Kirk A. Frey

Kirk A. Frey's AcademicInfluence.com Rankings

Kirk A. Frey

Philosophy

#7439

World Rank

#10655

Historical Rank

Logic

#4490

World Rank

#5794

Historical Rank

philosophy Degrees

Kirk A. Frey

Biology

#10104

World Rank

#13400

Historical Rank

Neuroscience

#1533

World Rank

#1584

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Kirk A. Frey's Degrees

PhD Neuroscience Stanford University
Doctorate Medicine Stanford University

Why Is Kirk A. Frey Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kirk A. Frey's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease (1997) (1671)
A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. (1995) (1009)
Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations (1997) (530)
Positron emission tomographic analysis of cerebral structures activated specifically by repetitive noxious heat stimuli. (1994) (506)
Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation (2001) (496)
Anatomic standardization: linear scaling and nonlinear warping of functional brain images. (1994) (423)
In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease (1996) (369)
Hippocampal Inactivation Disrupts the Acquisition and Contextual Encoding of Fear Extinction (2005) (368)
History of falls in Parkinson disease is associated with reduced cholinergic activity (2009) (354)
Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography (1991) (351)
In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease (1999) (336)
Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging (1996) (308)
Decreased striatal dopaminergic innervation in REM sleep behavior disorder (2000) (284)
Automated detection of the intercommissural line for stereotactic localization of functional brain images. (1993) (271)
Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease (2010) (267)
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. (2015) (238)
Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease (2006) (237)
Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease (1996) (225)
Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis (1995) (212)
The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. (1995) (207)
Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease (2012) (204)
In vivo cerebral metabolism and central benzodiazepine‐receptor binding in temporal lobe epilepsy (1993) (194)
Cerebral Glucose Metabolic Features of Parkinson Disease and Incident Dementia: Longitudinal Study (2011) (193)
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome (2006) (192)
Brain PET in suspected dementia: patterns of altered FDG metabolism. (2014) (181)
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease (2003) (180)
Changes in [3H]muscimol binding in substantia nigra, entopeduncular nucleus, globus pallidus, and thalamus after striatal lesions as demonstrated by quantitative receptor autoradiography (1983) (178)
Mutual Information for Automated Unwarping of Rat Brain Autoradiographs (1997) (169)
Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. (1997) (167)
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options (2009) (165)
Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review (2015) (157)
A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. (2007) (156)
Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia (2012) (155)
Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer: A Phase 2 Clinical Trial (2017) (153)
Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers (2006) (151)
Increased ventral striatal monoaminergic innervation in Tourette syndrome (2003) (149)
Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. (1996) (145)
Localization of muscarinic M3 receptor protein and M3 receptor binding in rat brain (1994) (143)
Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia (1999) (139)
Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? (1995) (139)
Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. (2013) (136)
Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex (2000) (133)
In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. (1994) (130)
PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. (1995) (128)
Quantitative autoradiography of [3H]muscimol binding in rat brain. (1981) (122)
Striatal dopaminergic abnormalities in human cocaine users. (1999) (120)
Differentiation of Radioligand Delivery and Binding in the Brain: Validation of a Two-Compartment Model for [11C]Flumazenil (1991) (114)
Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. (1997) (112)
Spared Caudal Brainstem SERT Binding in Early Parkinson's Disease (2008) (112)
Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. (2015) (111)
Parametric in vivo imaging of benzodiazepine receptor distribution in human brain (1991) (110)
Protein synthesis in the amygdala, but not the auditory thalamus, is required for consolidation of Pavlovian fear conditioning in rats (2003) (109)
11C-DTBZ and 18F-FDG PET measures in differentiating dementias. (2005) (108)
Kinetic Modeling of N-[11C]Methylpiperidin-4-yl Propionate: Alternatives for Analysis of an Irreversible Positron Emission Tomography Tracer for Measurement of Acetylcholinesterase Activity in Human Brain (1999) (104)
In Vivo Imaging of Human Cholinergic Nerve Terminals with (–)-5-18F-Fluoroethoxybenzovesamicol: Biodistribution, Dosimetry, and Tracer Kinetic Analyses (2014) (104)
[3H]methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity (1995) (103)
Kinetic Evaluation of [11C]Dihydrotetrabenazine by Dynamic PET: Measurement of Vesicular Monoamine Transporter (1996) (103)
Temporal lobe central benzodiazepine binding in unilateral mesial temporal lobe epilepsy (1995) (100)
Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. (2011) (99)
Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers (2006) (97)
Gait speed in Parkinson disease correlates with cholinergic degeneration (2013) (96)
In vivo Muscarinic Cholingeric Receptor Imaging in Human Brain with [11C]Scopolamine and Positron Emission Tomography (1992) (96)
Extra‐nigral pathological conditions are common in Parkinson's disease with freezing of gait: An in vivo positron emission tomography study (2014) (95)
Metabotropic Glutamate Agonist-Induced Rotation: A Pharmacological, FOS Immunohistochemical, and [14C]-2-Deoxyglucose Autoradiographic Study (1997) (95)
Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? (2013) (92)
Cholinergic system changes of falls and freezing of gait in Parkinson's disease (2019) (92)
Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia (2012) (92)
Imaging the vesicular monoamine transporter. (2001) (91)
Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific (1995) (91)
Stereotactic PET atlas of the human brain: aid for visual interpretation of functional brain images. (1994) (91)
Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. (2008) (90)
Diabetes is associated with postural instability and gait difficulty in Parkinson disease. (2013) (90)
High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. (2000) (89)
Equilibrium versus Compartmental Analysis for Assessment of the Vesicular Monoamine Transporter Using (+)-α-[11C]Dihydrotetrabenazine (DTBZ) and Positron Emission Tomography (1997) (87)
Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers (2001) (86)
[18F]fluoroethoxy‐benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses (1998) (85)
Decreased striatal monoaminergic terminals in Huntington disease (2000) (84)
β‐amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia (2013) (80)
Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. (2000) (79)
Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. (1996) (78)
Probable diffuse Lewy body disease presenting as REM sleep behavior disorder (1997) (77)
Assessment of Extrastriatal Vesicular Monoamine Transporter Binding Site Density Using Stereoisomers of [11C]Dihydrotetrabenazine (1999) (77)
Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. (1995) (77)
Differentiating Alzheimer’s disease from dementia with Lewy bodies and Parkinson’s disease with (+)-[11C]dihydrotetrabenazine positron emission tomography (2008) (76)
Positron emission tomography measures of benzodiazepine receptors in Huntington's disease (1993) (76)
Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects (2001) (75)
Insomnia and sleepiness in Parkinson disease: associations with symptoms and comorbidities. (2013) (74)
Initial agonist treatment of Parkinson disease (2003) (73)
Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. (2014) (73)
Reduced γ-aminobutyric acidA-benzodiazepine binding sites in insular cortex of individuals with panic disorder (2007) (72)
Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET (2001) (70)
High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. (2014) (70)
[11C]Tropanyl Benzilate—Binding to Muscarinic Cholinergic Receptors: Methodology and Kinetic Modeling Alternatives (1994) (69)
[15O]H2O positron emission tomography determination of cerebral blood flow during balloon test occlusion of the internal carotid artery. (1994) (69)
Autoradiographic mapping of M3 muscarinic receptors in the rat brain. (1993) (69)
Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease (2014) (69)
In Vivo Imaging of Vesicular Monoamine Transporters in Human Brain Using [11C]Tetrabenazine and Positron Emission Tomography (1993) (68)
Striatal presynaptic monoaminergic vesicles are not increased in Tourette’s syndrome (1999) (66)
GABAA receptor abnormalities in Prader–Willi syndrome assessed with positron emission tomography and [11C]flumazenil (2004) (66)
Reliability of Repeated Cognitive Assessment of Dementia Using a Brief Computerized Battery (2011) (65)
Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment (2018) (61)
Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles. (2012) (60)
Imaging of Cholinergic and Monoaminergic Neurochemical Changes in Neurodegenerative Disorders (2007) (59)
Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. (2010) (59)
Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease (2017) (59)
In vivo imaging of the brain vesicular monoamine transporter. (1995) (59)
Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. (2002) (59)
Early menopausal hormone use influences brain regions used for visual working memory (2010) (59)
In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses (2006) (59)
Neuroimaging of Tourette Syndrome (2006) (58)
Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. (2010) (55)
Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography (1996) (55)
FDG PET imaging of childhood sarcomas (2009) (55)
Lymphatic Mapping and Sentinel Lymph Node Biopsy for Patients With Local Recurrence After Breast-Conservation Therapy (2006) (55)
Clinical markers for identifying cholinergic deficits in Parkinson's disease (2015) (54)
Striatal and Cortical β‐Amyloidopathy and Cognition in Parkinson's Disease (2016) (53)
Comparison of 18F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma (2007) (52)
In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography. (1992) (52)
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol. (1996) (51)
In Vivo Measurement of the Vesicular Monoamine Transporter in Schizophrenia (2000) (51)
Positron emission tomography imaging of (2R,3R)-5-[(18)F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. (2009) (50)
Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. (2005) (48)
Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. (2011) (47)
Cholinergic vesicular transporters in progressive supranuclear palsy (2002) (47)
Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome (2009) (47)
Neurochemical imaging of Alzheimer's disease and other degenerative dementias. (1998) (45)
Quantitative in vivo receptor binding III: Tracer kinetic modeling of muscarinic cholinergic receptor binding. (1985) (45)
Synthesis, in vivo biodistribution and dosimetry of [11C]N-methylpiperidyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonist. (1995) (45)
Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. (1996) (45)
Changes in global function and regional ventilation and perfusion on SPECT during the course of radiotherapy in patients with non-small-cell lung cancer. (2012) (45)
In Vivo Quantification of Cerebral Muscarinic Receptors in Normal Human Aging Using Positron Emission Tomography and [11C]Tropanyl Benzilate (1996) (45)
SNM Practice Guideline for Brain Death Scintigraphy 2.0 (2012) (43)
Quantification of Muscarinic Cholinergic Receptors with [11C]NMPB and Positron Emission Tomography: Method Development and Differentiation of Tracer Delivery from Receptor Binding (1998) (43)
Basal ganglia glucose utilization after recent precentral ablation in the monkey (1985) (43)
Neuroimaging in Dementia with Lewy Bodies: Metabolism, Neurochemistry, and Morphology (2002) (43)
Quantitative in vivo receptor binding. II. Autoradiographic imaging of muscarinic cholinergic receptors (1985) (43)
Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder. (2007) (42)
Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. (2009) (42)
Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias (2002) (41)
Barbiturate-enhanced detection of brain lesions by carbon-14-labeled 2-deoxyglucose autoradiography. (1983) (41)
Receptor Binding Techniques (1997) (40)
Semiquantification and Classification of Local Pulmonary Function by V/Q Single Photon Emission Computed Tomography in Patients with Non-small Cell Lung Cancer: Potential Indication for Radiotherapy Planning (2011) (38)
Regional vesicular acetylcholine transporter distribution in human brain: A [18F]fluoroethoxybenzovesamicol positron emission tomography study (2018) (38)
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of l-DOPA and pramipexole (2003) (38)
Quantitative autoradiography of muscarinic cholinergic receptor binding in the rat brain: distinction of receptor subtypes in antagonist competition assays. (1992) (37)
The value of 99mTc-MAA SPECT/CT for lung shunt estimation in 90Y radioembolization: a phantom and patient study (2018) (36)
Effect of hyperglycemia on brain and liver 18F-FDG standardized uptake value (FDG SUV) measured by quantitative positron emission tomography (PET) imaging. (2017) (35)
Pattern of cardiac sympathetic denervation in idiopathic Parkinson disease studied with 11C hydroxyephedrine PET. (2012) (34)
Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. (1995) (33)
In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. (2010) (33)
A densitometer for quantitative autoradiography (1983) (33)
The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation (1998) (33)
Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV (2018) (32)
Quantitative autoradiography of neurotransmitter receptors using tritium-sensitive film. (1981) (32)
Crossed cerebellar diaschisis: occurrence and resolution demonstrated with PET during carotid temporary balloon occlusion. (1992) (32)
The Role of Serotonin in Sleep Disordered Breathing Associated with Parkinson Disease: A Correlative [11C]DASB PET Imaging Study (2012) (30)
Experimental hemiplegia in the monkey: Basal ganglia glucose activity during recovery (1987) (29)
Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease. (2017) (28)
Diminished striatal [123I]iodobenzovesamicol binding in idiopathic cervical dystonia (2003) (28)
Changes in functional lung regions during the course of radiation therapy and their potential impact on lung dosimetry for non-small cell lung cancer. (2014) (28)
Quantitative in vivo receptor binding (1986) (28)
Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease. (2016) (27)
Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepatic encephalopathy (1997) (27)
In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter. (1996) (26)
Educational attainment and motor burden in Parkinson's disease (2015) (26)
Predictive models for regional hepatic function based on 99mTc-IDA SPECT and local radiation dose for physiologic adaptive radiation therapy. (2013) (26)
Mutual information for automated multimodal image warping (1996) (25)
A sequential double-label autoradiographic method that quantifies altered rates of regional glucose metabolism (1985) (25)
Prevalence of impaired odor identification in Parkinson disease with imaging evidence of nigrostriatal denervation (2016) (24)
Comparison of Single Time-Point [111-In] Pentetreotide SPECT/CT With Dual Time-Point Imaging of Neuroendocrine Tumors (2011) (24)
The role of positron emission tomography imaging in movement disorders. (2003) (24)
Muscarinic Receptor Loss and Preservation of Presynaptic Cholinergic Terminals in Hippocampal Sclerosis (1999) (24)
ACR-ASNR Practice Parameter for Brain PET/CT Imaging Dementia. (2016) (23)
Thinning of the Motor–Cingulate–Insular Cortices in Siblings Concordant for Tourette Syndrome (2009) (23)
Stereotaxic Summation Analysis of Human Cerebral Benzodiazepine Binding Maps (1996) (23)
Chronic electrical stimulation reverses deafness-related depression of electrically evoked 2-deoxyglucose activity in the guinea pig inferior colliculus (1993) (22)
Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and posterior cingulate cholinergic activity. (2011) (22)
Advanced squamous cell carcinoma of the oropharynx: Efficacy of positron emission tomography and computed tomography for determining primary tumor response during induction chemotherapy (2009) (21)
SNMMI/ABNM Joint Position Statement on Optimizing Training in Nuclear Medicine in the Era of Hybrid Imaging (2012) (21)
Neurochemical imaging of dementias. (2004) (20)
Utility of SPECT/CT with Meckel’s scintigraphy (2009) (20)
Synthesis, 18F-Labeling, and Biological Evaluation of Piperidyl and Pyrrolidyl Benzilates as in Vivo Ligands for Muscarinic Acetylcholine Receptors (2000) (20)
Assessing Mild Cognitive Impairment with Amyloid and Dopamine Terminal Molecular Imaging (2013) (20)
2-Year Natural Decline of Cardiac Sympathetic Innervation in Idiopathic Parkinson Disease Studied with 11C-Hydroxyephedrine PET (2017) (20)
Co-Registration of MRI and Autoradiography of Rat Brain in Three-Dimensions Following Automatic Reconstruction of 2D Data Set (1995) (19)
Topography of Cholinergic Changes in Dementia With Lewy Bodies and Key Neural Network Hubs. (2020) (19)
Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias (2017) (19)
Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. (2019) (18)
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor – a pharmacokinetic study (2005) (18)
Development of a tomographic myelin scan (1981) (18)
Imaging amyloidopathy in Parkinson disease and parkinsonian dementia syndromes (2015) (18)
[14C]-2-deoxyglucose uptake in monkeys with hypotonic hemiplegia after precentral or postcentral lesions (1980) (18)
Imaging of monoaminergic and cholinergic vesicular transporters in the brain. (1998) (17)
()-α-[11C]Dihydro- tetrabenazine PET imaging in familial paroxysmal dystonic choreoathetosis (1999) (17)
Procedure guideline for brain death scintigraphy. (2003) (17)
Scintigraphic portrayal of beta receptors in the heart. (1991) (17)
Intrastriatal Neurotoxin Injections Reduce in Vitro and in Vivo Binding of Radiolabeled Rotenoids to Mitochondrial Complex I (1997) (17)
Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease. (2012) (16)
First-in-Human Studies of [ 18 F] Fluorohydroxyphenethylguanidines (2018) (16)
Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson’s disease (2021) (16)
Heterogeneity of cholinergic denervation in Parkinson disease (2012) (15)
Data Extraction from Brain PET Images Using Three-Dimensional Stereotactic Surface Projections (1998) (15)
Gender differences in cholinergic and dopaminergic deficits in Parkinson disease (2013) (15)
A Novel Time–Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE (2020) (15)
First-in-Human Studies of [18F] Fluorohydroxyphenethylguanidines: Positron Emission Tomography Radiotracers for Quantifying Regional Cardiac Sympathetic Nerve Density (2018) (15)
Effects of Tumor Burden on Reference Tissue Standardized Uptake for PET Imaging: Modification of PERCIST Criteria. (2018) (14)
Cerebellar metabolic reduction in Alzheimer's disease and data normalization. (1998) (14)
Non-exercise physical activity attenuates motor symptoms in Parkinson disease independent from nigrostriatal degeneration. (2015) (14)
Evaluation of [18F]N-methyl-lansoprazole as a tau PET imaging agent in first-in-human studies. (2020) (14)
Apathy rating scores and β-amyloidopathy in patients with Parkinson disease at risk for cognitive decline (2019) (14)
Thalamic, brainstem, and cerebellar glucose metabolism in the hemiplegic monkey (1988) (13)
Imaging of acute pulmonary embolism (2013) (13)
Advanced age, cardiovascular risk burden, and timed up and go test performance in Parkinson disease. (2014) (13)
Kinetic Evaluation of Positron-Emitting Muscarinic Receptor Ligands Employing Direct Intracarotid Injection (1996) (13)
Metabolic response assessment with 18F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer (2015) (12)
Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment. (2010) (12)
History of falls in Parkinson disease is associated with reduced cholinergic but not nigrostriatal dopaminergic activity (2009) (12)
Demonstration of prosthetic activation of central auditory pathways using [14C]‐2‐Deoxyglucose (1990) (12)
A regional metabolic contrast method for the study of brain pathology (1984) (12)
An updated radiosynthesis of [18F]AV1451 for tau PET imaging (2017) (11)
Decreased Lung Perfusion After Breast/Chest Wall Irradiation: Quantitative Results From a Prospective Clinical Trial. (2017) (11)
ABNM Position Statement: Nuclear Medicine Professional Competency and Scope of Practice (2011) (10)
Equilibrium analysis of [11C]PIB studies (2008) (10)
Proceedings of the International Cancer Imaging Society (ICIS) 16th Annual Teaching Course (2016) (10)
Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC) (2020) (9)
Postmenopausal hormone treatment alters neural pathways but does not improve verbal cognitive function (2018) (9)
ACR-ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. (2017) (9)
Post‐Mortem evaluation of amyloid‐dopamine terminal positron emission tomography dementia classifications (2015) (9)
Biodistribution of 99mTc-MAA on SPECT/CT performed for 90Y-radioembolization therapy planning: a pictorial review (2017) (9)
Human brain receptor distribution. (1986) (8)
Synthesis and biological evaluation in mice of (2-[11C]methoxy)-6',7'-dihydrorotenol, a second generation rotenoid for marking mitochondrial complex I activity. (1995) (8)
Technetium-99m-N1-(2-mercapto-2-methylpropyl)-N2-(2-propargylthio-2- methylpropyl)-1,2-benzenediamine (T691): preclinical studies of a potential new tracer of regional cerebral perfusion. (1992) (8)
The neurochemistry of therapeutics: Levodopa pharmacodynamics in Parkinson's disease (2001) (7)
Classification of ADNI PET images via regularized 3D functional data analysis (2017) (7)
Agreement among neuropsychological and behavioral data and PiB findings in diagnosing Frontotemporal Dementia (2017) (7)
PET imaging of the vesicular acetylcholine transporter (2012) (7)
Interpretation of metabolic abnormalities in Alzheimer's disease using three-dimensional stereotactic surface projections (3D-SSP) and normal database (1995) (7)
Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson Disease. (2017) (7)
First-in-human studies of 18F-hydroxyphenethylguanidines: PET radiotracers for quantifying cardiac sympathetic nerve density. (2016) (7)
Amyloid Imaging in Dementia: Contribution or Confusion? (2015) (7)
(+)-alpha-[11C]Dihydrotetrabenazine PET imaging in familial paroxysmal dystonic choreoathetosis. (1999) (7)
Effects of plasma glucose levels on regional cerebral 18F-fluorodeoxyglucose uptake: Implications for dementia evaluation with brain PET imaging (2019) (7)
Utility of delayed whole-body bone scintigraphy after directed three-phase scintigraphy. (2009) (7)
Reduction of presynaptic monoaminergic vesicles in the striata of parkinsonian patients and in normal human aging. (1995) (6)
Staging of Differentiated Thyroid Carcinoma Using Diagnostic (2010) (6)
Evaluation of methoxytetrabenazine as an in vivo tracer of monoamine nerve terminal integrity. (1994) (6)
Society of Nuclear Medicine Procedure Guideline for Brain Death Scintigraphy version 1 . 0 , approved February 25 , 2003 (2003) (6)
Color discrimination errors associate with axial motor impairments in Parkinson's Disease (2017) (6)
Pharmacological characterization of PD102807: An m4 subtype selective muscarinic antagonist (1997) (6)
Tomography Scans During and After Radiation-Based Therapy in Patients With Non-Small-Cell Lung Cancer (2007) (6)
Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain (2004) (6)
A Pipeline for Automated Voxel Dosimetry: Application in Patients with Multi-SPECT/CT Imaging After 177Lu-Peptide Receptor Radionuclide Therapy (2022) (5)
False Positive Diagnosis of Metastatic Esophageal Carcinoma on Positron Emission Tomography: A Case Report of Cholecystitis Simulating a Hepatic Lesion (2010) (5)
Results of multi-center clinical trials comparing four 18F PET amyloid-imaging agents: Preclinical to clinical correlations (2008) (5)
FDG-PET/CT during Radiation Therapy to Predict Survival and Guide Individualized Adaptive Dose Escalation in Patients with Non–small-cell Lung Cancer (2009) (5)
Dopamine depletion increases in vivo [11C]DTBZ binding in awake rat brain (2008) (5)
Radiosynthesis and comparisons in the biodistribution of carbon‐11 labeled muscarinic antagonists: (+)2α‐tropanyl benzilate and N‐methyl‐4‐piperidyl benzilate (1989) (5)
Correlation of Continuous EEG Monitoring with [O-15]H2O Positron Emission Tomography Determination of Cerebral Blood Flow during Balloon Test Occlusion of the Internal Carotid Artery (1998) (5)
Autoradiographic quantification of muscarinic cholinergic synaptic markers in bat, shrew, and rat brain (1994) (5)
Vertebral body hemangioma visualized on Tc-99m HMPAO-labeled leukocyte SPECT/CT. (2008) (4)
Neuroimaging in neurotoxicology. (2000) (4)
240. Pet measures of monoaminergic synaptic density in bipolar I disorder: Relationship with age of onset (1998) (4)
Quantifying cardiac sympathetic denervation: first studies of 18F-fluorohydroxyphenethylguanidines in cardiomyopathy patients (2021) (4)
Quantitative in vivo receptor binding IV: Detection of muscarinic receptor down-regulation by equilibrium and by tracer kinetic methods (1991) (4)
(-)-6', 7'-[11C]dihydroroten-12α-ol ((-)-[11C]DHROL) for in vivo measurement of mitochondrial complex I (1999) (4)
Decreased striatal monoaminergic presynaptic terminals in OPCA and MSA demonstrated with [11C]dihydrotetrabenazine and PET. (1995) (4)
Erratum: Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers (Psychopharmacology (2006) 185 (327-338) DOI: http//dx.doi.org/10.1007/s00213-006-0330-6) (2006) (4)
Predictive Models for Regional Hepatic Function Based upon 99mTc-IDA SPECT and Local Radiation Dose for Physiological Adaptive RT (2013) (3)
Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. (2016) (3)
Focal hyperemia on RBC blood-flow imaging. A scintigraphic marker of arterioportal venous shunting in hepatic cavernous hemangiomas? (1997) (3)
[O-15]H2O Positron Emission Tomography Determination of Cerebral Blood Flow Reserve after Intravenous Acetazolamide during Balloon Test Occlusion of the Internal Carotid Artery (1998) (3)
Molecular Imaging of Extrapyramidal Movement Disorders. (2017) (3)
Management of Diabetes Mellitus Before 18F-Fluorodeoxyglucose PET/CT: A Nationwide Patient-Centered Assessment of Approaches to Examination Preparation. (2019) (3)
PET Amyloid Analyses (2016) (3)
Kinetic evaluation of [C-11]dihydrotetrabenazine (DTBZ) by dynamic PET : a marker for the vesicular monoamine transporter. (1995) (3)
Surface projection maps of cortical amyloid binding reveal canonical patterns in neurodegenerative dementias (2012) (3)
5-tert-Butyl-2-(4'-[18F]fluoropropynylphenyl)-1,3-dithiane oxides: potential new GABA A receptor radioligands. (2008) (3)
Basal ganglia glucose metabolic and single neural unit activity in experimental hemiplegia. (1984) (3)
Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against. (2002) (3)
Hepatic Function Model Based Upon HIDA SPECT and Dose for Physiological Adaptive RT. (2013) (2)
Tritium labeling of potential lipophilic myelin probes (1984) (2)
Parkinson Dementia: PET Findings (2014) (2)
Radiotracers and analytical approaches in positron and single-photon emission tomography. (2000) (2)
Progression of regional cortical cholinergic denervation in Parkinson disease: a longitudinal acetycholinesterase 11C-PMP PET study (2018) (2)
Imaging VMAT2 in Parkinson disease with [F-18]AV-133 (2008) (2)
Respiratory motion gated PET with end-expiratory, amplitude based gating (2009) (2)
Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors (2022) (2)
Molecular Imaging of Extrapyramidal Movement Disorders With Dementia: The 4R Tauopathies. (2021) (2)
Imaging butyrylcholinesterase activity in Alzheimer's disease (2006) (2)
Gait Speed Is Preserved in Oligosystem Compared to Multisystem Neurodegeneration in Parkinson Disease (P04.165) (2013) (2)
158. Decreased vesicular monoamine transporter density in schizophrenic prefrontal cortex (2000) (2)
Clinical correlation of multivariate spatial covariance analysis of 18F-FEOBV VAChT PET in Parkinson disease (2016) (2)
Synthesis, (18)F-labeling, and biological evaluation of piperidyl and pyrrolidyl benzilates as in vivo ligands for muscarinic acetylcholine receptors. (2000) (2)
Apathy but not depression is associated with amyloidopathy in Parkinson disease at risk for dementia (2015) (2)
Single-Photon Emission Computed Tomography/Computed Tomography as a Problem-Solving Tool in Patients With Suspected Acute Cholecystitis (2013) (2)
Impaired color perception is associated with more severe nigrostriatal denervation in Parkinson disease (2013) (2)
Progression of regional cortical cholinergic denervation in Parkinson's disease. (2022) (2)
Positron Emission Tomography (2019) (1)
Autoimmune limbic encephalitis detected on FDG brain scan performed for the evaluation of dementia. (2015) (1)
Updates in Molecular Brain Imaging. (2017) (1)
The phosphoinositide-linked CNS muscarinic receptor. (1988) (1)
Using FDG-PET Acquired During the Course of Radiation Therapy to Individualize Adaptive Radiation Dose Escalation in Patients with Non-Small Cell Lung Cancer (2010) (1)
PET cardiac sympathetic imaging with 11C-hydroxyephedrine in idiopathic Parkinson's disease (2011) (1)
Odor identification is a more robust measure of forebrain cholinergic activity than odor memory/discrimination tests in Parkinson disease (2013) (1)
Kinetic evaluation of [C-11] dihydrotetrabenazine : a PET ligand for assessing the vesicular monoamine transporter. (1995) (1)
Slowing Parkinson’s disease progression: Recent dopamine agonist trials: Reply from the Authors (2004) (1)
PIB PET 3-site stability study (2007) (1)
Inter-method Comparison and Optimization of [18F] FDG PET Metabolic Response Assessment in Non-Small Cell Lung Cancer. (2013) (1)
Cerebellar acetylcholinesterase activity and parkinsonian motor impairment (2008) (1)
Amyloid PET imaging: a challenge for research in clinical neuroimaging (2015) (1)
Ratings of activities of daily living are associated with cortical cholinergic but not with the degree of nigrostriatal dopaminergic activity in Parkinson disease (2009) (1)
Comparing Fludeoxyglucose F 18 – PET Assessment of Regional Cerebral Glucose Metabolism and [ 11 C ] Dihydrotetrabenazine – PET in Evaluation of Early Dementia and Mild Cognitive Impairment (2010) (1)
Comorbid cortical {beta}-amyloid plaques affect postural instability and gait disorder symptoms in Parkinson disease (2012) (1)
Methods in Positron Emission Tomography (1999) (1)
Brain benzodiazepine binding sites in panic disorder (2000) (1)
Neuroimaging of epilepsy, movement disorders, and degenerative diseases (1993) (1)
In vitro and in vivo binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is strereospecific. (1995) (1)
18F-FDG PET/CT Demonstrates Efficacy and Limitations of Hepatic Arterial Infusion Chemotherapy for Treating Colorectal Liver Metastases (2010) (1)
The Additional Value of V/Q SPECT over Q SPECT Alone for Pulmonary Function Mapping before, during and after Radiotherapy in Patients with Non–small Cell Lung Cancer (2009) (0)
Differentiation of Lewy body dementia from Parkinson's disease with [C-11]DTBZ PET (2005) (0)
Autoradiographic distinction of high and low affinity muscarinic receptors by the m1-selective ligand PD150714 (1995) (0)
Both cortical cholinergic denervation and cortical {beta}-amyloid plaques contribute to cognitive impairment in Parkinson disease (2012) (0)
Differential diagnosis of renal masses with PET/CT (2006) (0)
Routine determination of pulmonary aerosol clearance in V/Q SPECT studies (2008) (0)
177Lu-DOTATATE Theranostics (2023) (0)
The Prevalence of Impaired Olfaction in Parkinson's Disease Is Higher Than Previously Estimated (P07.129) (2012) (0)
Erratum: Hippocampal inactivation disrupts the acquisition and contextual encoding of fear extinction (Journal of Neuroscience (September 28, 2005) (8978-8987)) (2005) (0)
Contents of the American Journal of Psychiatry (2005) (0)
85. In vivo measurement of presynaptic dopamine innervation in schizophrenia (1998) (0)
Reverse Translation in Parkinson Disease (2016) (0)
Single time-point planar and SPECT/CT 111-In pentetreotide scintigraphy: Does it have advantages over dual time-point planar and SPECT imaging? (2008) (0)
Effect of serum blood glucose on SUV measurements: implications in quantitative brain imaging and implementation of PERCIST criteria (2016) (0)
Agonists versus levodopa in PD: the thrilla of whitha: Reply from the Authors (2003) (0)
Utilization of SPECT/CT for the evaluation of suspected acute cholecystitis in problematic cases (2011) (0)
Pulmonary functional map on V/Q SPECT and TGFβ1 during radiotherapy and post-treatment lung function in patients with non-small cell lung cancer. (2009) (0)
Heterogeneity of neurodegeneration in Parkinson disease: Variable degree of dopaminergic versus cholinergic denervation (2009) (0)
Differential cholinergic systems’ changes in progressive supranuclear palsy versus Parkinson’s disease: an exploratory analysis (2022) (0)
SU‐FF‐J‐34: Can Functional Imaging Be Used to Individualize Adaptive Radiation Therapy for Non‐Small Cell Lung Cancer? (2006) (0)
Cortical and subcortical cholinergic innervation in normal aging (2010) (0)
Gender Differences in Dopaminergic and Cholinergic Integrity in Parkinson Disease (P06.080) (2013) (0)
Physiological and Biochemical Measurements Using Positron Emission Tomography (1999) (0)
Diagnostic value of 111-In pentetreotide SPECT/CT fusion imaging in the evaluation of neuroendocrine tumors in routine clinical practice (2007) (0)
177 Lu-DOTATATE Theranostics Predicting Renal Dosimetry From Pretherapy 68 Ga-DOTATATE PET and Clinical Biomarkers (2023) (0)
Older age of Parkinson's disease onset associated with increased cognitive impairment, even in patients without dementia (1999) (0)
Cardiovascular risk factors associate with cholinergic denervation in Parkinson disease (P2.152) (2015) (0)
In vivo assessment of multiple neurodegenerations and cognitive impairment in Parkinson disease (2014) (0)
in Normal &ng, AlzheimJs Disease, and Parlunson's Disease (1996) (0)
Applications of SPECT-CT in lymphoscintigraphy (2006) (0)
Diabetes Is Associated with Increased Central Neurotoxicity in Parkinson Disease: A Case-Control Study (P06.098) (2013) (0)
Synthesis of [11C]rotenone and preliminary biodistribution studies in mice and monkey (1994) (0)
Evaluation of Extrastriatal Specific Binding of [11C]Dihydrotetrabenazine Using Active and Inactive Enantiomers (2001) (0)
Cholinergic Integrity And Visual Hallucinations In Parkinson Disease (S18.004) (2014) (0)
Lower Education Status Associates With Axial Motor Burden In Parkinson Disease (P5.265) (2014) (0)
Selective hyposmia and striatal monoaminergic vesicular binding binding in Parkinson disease (2008) (0)
Cerebellar vermis vesicular acetylcholine transporter expression and parkinsonian motor impairment (2014) (0)
Striatal vesicular acetylcholine transporter expression and cognitive function in Parkinson disease (2014) (0)
PET imaging of metastatic paraganglioma using novel 3-[18F]fluoro-para-hydroxyphenethylguanidine (3-[18F]pHPG) radiotracer (2022) (0)
Thalamic GABAa Receptor Expression is Inversely Correlated with Axial Motor Impairments in Parkinson Disease (P6.082) (2015) (0)
The Correlation of Pulmonary FDG PET and Perfusion SPECT Imaging During Radiotherapy for Non-small Cell Lung Cancer (2010) (0)
Increased frontal lobe white matter lesion burden is associated with increased cortical and raphe nucleus serotonin transporter expression in normal elderly (2012) (0)
Decreased Vestibular Efficacy Contributes To Balance Impairment in Parkinson Disease (PD4.009) (2012) (0)
Use of exploratory INDs in evaluation of 18F-labeled PET amyloid plaque imaging agents (2008) (0)
Dopaminergic and cholinergic correlates of rhythmic foot oscillation control in Parkinson disease (2010) (0)
Postural sensory efficacy and striatal dopaminergic innervation in normal older adults (2010) (0)
Limitations of delayed SPECT/CT in the evaluation of parathyroid adenomas (2008) (0)
In Vivo Mapping of Cholmergic Termina in Normal & ng , Alzheimer ' s Disease , and Parlunson ' s Disease l eri (0)
REM sleep behavior disorder is associated with cortical cholinergic deficit in Parkinson's disease without dementia (2010) (0)
WE‐A‐217A‐04: Hepatic Function Estimated from HIDA SPECT for Assessment of Liver Response to Radiation Therapy (2012) (0)
Invited commentary on "Structural and functional imaging in parkinsonian syndromes". (2014) (0)
FDG PET Imaging of Childhood Sarcomas 225 (2009) (0)
The Michigan New Technology Training and Research (MNTR) Translational Program in Nuclear Medicine (Final Report) (2018) (0)
Decreased Lung Perfusion Following Breast/Chest Wall Irradiation: Preliminary Results of a Prospective Clinical Trial (2014) (0)
Regional white matter lesions and Pittsburgh compound B retention in cognitively impaired elderly (2013) (0)
Reply: Cognition and olfaction in Parkinson's disease (2010) (0)
Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease. (2002) (0)
A Pilot 11C-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer (2013) (0)
Molecular Imaging of Neurodegenerative Parkinsonism. (2021) (0)
Development of a blood test to predict patient [11C]PBR28 binding patterns prior to clinical PET imaging (2012) (0)
More severe parkinsonism is associated with lower physical activity-related energy expenditure in PD (P7.289) (2015) (0)
ABNM CertLink: Update and "By the Numbers". (2022) (0)
47: Pilot Study on FDG-PET Acquired During and After Fractionated Radiation in Patients With Non-Small Cell Lung Cancer (NSCLC) (2006) (0)
Clinical Applications of Cerebral Positron Emission Tomography (1999) (0)
Regional white matter lesions and PIB retention in cognitively impaired elderly (2013) (0)
O1‐07‐06: Mild Dementia evaluated with [11C]DTBZ and [11C]PiB positron emission tomography (2011) (0)
Activation of the auditory brainstem of deafened guinea pigs with cochlear stimulation a carbon 14 2 deoxyglucose study (1989) (0)
Posterior cortical hypometabolism precedes mixed subcortical-cortical metabolic changes in incident dementia in Parkinson disease (2008) (0)
Invited oral presentations (1997) (0)
PET neurochemical vs. clinical phenotypes in mild-early dementia (2009) (0)
Striatal dopaminergic correlates of the Montreal Cognitive Assessment test and the Mini Mental State Exam in Parkinson disease: A [11C]-DTBZ PET study (2012) (0)
Presence and intensity of tremor reflects subcortical cholinergic but not nigrostriatal dopaminergic innervation changes in Parkinson disease (2010) (0)
[11C]PiB in patients with amnestic and non-amnestic MCI (2009) (0)
Technical considerations for SPECT/CT in hepatobiliary imaging (2008) (0)
Diabetes Is Associated with Bradykinesia and Postural Instability and Gait Difficulty in Parkinson Disease Independent of Nigrostriatal Dopaminergic Denervation: A Case-Control Study (P07.125) (2012) (0)
Stereospecificity of in vitro and in vivo binding of isomers of alpha-[C-11]dihydrotetrabenazine alpha -[C-11]DTBZ) to vesicular monoamine transporters. (1995) (0)
Diagnostic yield of whole-body 18F-FDG PET/CT in patients with suspected cardiac sarcoidosis. (2023) (0)
Mild Dementia evaluated with [11C]DTBZ and [11C]PiB positron emission tomography (2011) (0)
Imaging Cognitive Dysfunction in Parkinson's Disease (2011) (0)
Inter-method Variability of [18F]FDG PET Metabolic Response Assessment of Non-small Cell Lung Cancer (NSCLC) (2011) (0)
Striatal and cortical amyloidopathy and cognitive functions in Parkinson disease at risk of dementia (2015) (0)
In vivo [C-11]dihydrotetrabenazine binding is unaffected by chronic L-DOPA or deprenyl treatment (1995) (0)
Bradykinesia, Rigidity, and Postural Instability and Gait Difficulty Occur More Commonly in Men with Parkinson Disease Compared to Women Independent of Nigrostriatal Dopaminergic Denervation (P06.044) (2012) (0)
Interval Changes Of Forebrain-Cortical Versus Brainstem-Thalamic Cholinergic Integrity In Parkinson Disease Progression (P2.007) (2014) (0)
Cardiac post-ganglionic sympathetic denervation correlates selectively with REM sleep behavior disorder symptoms in Parkinson disease. (2015) (0)
Regional covariance of brain cholinergic terminal changes in Parkinson disease: an 18F-FEOBV PET study (2016) (0)
Development of a Tomographc Myelin Scan (1981) (0)
In Vivo Imaging of Benzodiazepine Receptors with Positron Emission Tomography (2020) (0)
Pattern of cardiac s ympathetic Denervation in idiopathic Parkinson Disease s tudied with (2012) (0)
Reply: Alzheimer Disease: Approaches to Early Diagnosis and High-Accuracy Imaging (2015) (0)
Cholinergic and dopaminergic PET imaging of gait in Parkinson disease (2010) (0)
Variability in foot-tapping as a new biomarker of nigrostriatal dopaminergic denervation in Parkinson's disease (2009) (0)
Cognitive correlates of posterior cingulate hypometabolism in Parkinson disease (2008) (0)
Twelfth annual symposia on etiology, pathogenesis, and treatment of parkinson's disease and etiology, pathogenesis, and treatment of Huntington's disease (1998) (0)
Reply (0)
Shape analysis method can be used for limited non-invasive estimation of striatal and cerebellar [11C]-PMP k3 hydrolysis rates (2011) (0)
H 20 Positron Emission Tomography Determination of Cerebral Blood Flow during Balloon Test Occlusion of the Internal Carotid Artery (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kirk A. Frey?

Kirk A. Frey is affiliated with the following schools:

University of Michigan

Kirk A. Frey's Academic­Influence.com Rankings

Kirk A. Frey's Degrees

Why Is Kirk A. Frey Influential?

Kirk A. Frey's Published Works

Published Works

What Schools Are Affiliated With Kirk A. Frey?

Kirk A. Frey's AcademicInfluence.com Rankings